Clinical Trial Detail

NCT ID NCT02981628
Title Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Children's Oncology Group
Indications

B-cell childhood acute lymphoblastic leukemia

Therapies

inotuzumab ozogamicin

Age Groups: child adult

Additional content available in CKB BOOST